TAK1-mediated autophagy and fatty acid oxidation prevent hepatosteatosis and tumorigenesis.
暂无分享,去创建一个
Mason R. Mackey | Dorothy D. Sears | Mark Ellisman | S. Akira | D. Brenner | M. Karin | J. Olefsky | K. Taniguchi | E. Park | E. Seki | Xuefeng Wu | K. Asahina | Ling Yang | W. Lagakos | Shuang Liang | Michael Pimienta | Bi Zhang | Jingyi Song | Sayaka Inokuchi-Shimizu | Y. Roh
[1] Amy Y. M. Au,et al. p53 status determines the role of autophagy in pancreatic tumour development , 2013, Nature.
[2] M. Pasparakis,et al. K63 polyubiquitination and activation of mTOR by the p62-TRAF6 complex in nutrient-activated cells. , 2013, Molecular cell.
[3] G. Russo,et al. AMP-activated protein kinase: a target for old drugs against diabetes and cancer. , 2013, Biochemical pharmacology.
[4] E. Park,et al. Transforming growth factor-β signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1. , 2013, Gastroenterology.
[5] O. Yoo,et al. TAK1 regulates autophagic cell death by suppressing the phosphorylation of p70 S6 kinase 1 , 2013, Scientific Reports.
[6] S. Kageyama,et al. p62/SQSTM1/A170: physiology and pathology. , 2012, Pharmacological research.
[7] H. Sakurai. Targeting of TAK1 in inflammatory disorders and cancer. , 2012, Trends in pharmacological sciences.
[8] Mark Ellisman,et al. Maintenance of metabolic homeostasis by Sestrin2 and Sestrin3. , 2012, Cell metabolism.
[9] Michael Karin,et al. A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. , 2012, Gastroenterology.
[10] Jianfeng Xu,et al. Suppression of Tak1 promotes prostate tumorigenesis. , 2012, Cancer research.
[11] D. Klionsky,et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) , 2012, Autophagy.
[12] Robert Clarke,et al. Guidelines for the use and interpretation of assays for monitoring autophagy , 2012 .
[13] R. Bronson,et al. Chronic Activation of mTOR Complex 1 Is Sufficient to Cause Hepatocellular Carcinoma in Mice , 2012, Science Signaling.
[14] A. Yoshimura,et al. TGFβ-activated kinase 1 (TAK1)-binding proteins (TAB) 2 and 3 negatively regulate autophagy. , 2012, Journal of biochemistry.
[15] J. Rain,et al. Inhibition of autophagy by TAB2 and TAB3 , 2011, The EMBO journal.
[16] N. Kneteman,et al. m-TOR inhibitors: what role in liver transplantation? , 2011, Journal of hepatology.
[17] Aleksey A. Porollo,et al. p62 is a key regulator of nutrient sensing in the mTORC1 pathway. , 2011, Molecular cell.
[18] Keiji Tanaka,et al. Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells , 2011, The Journal of cell biology.
[19] Y. Eishi,et al. Autophagy-deficient mice develop multiple liver tumors. , 2011, Genes & development.
[20] B. Viollet,et al. Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy , 2011, Science.
[21] D. Sabatini,et al. mTORC1 controls fasting-induced ketogenesis and its modulation by ageing , 2010, Nature.
[22] D. Sabatini,et al. mTOR: from growth signal integration to cancer, diabetes and ageing , 2010, Nature Reviews Molecular Cell Biology.
[23] F. Alt,et al. SIRT3 deacetylates mitochondrial 3-hydroxy-3-methylglutaryl CoA synthase 2 and regulates ketone body production. , 2010, Cell metabolism.
[24] G. Kroemer,et al. Autophagy and the integrated stress response. , 2010, Molecular cell.
[25] Michael Müller,et al. Peroxisome Proliferator-Activated Receptor Alpha Target Genes , 2010, PPAR research.
[26] Thomas J. Fuchs,et al. TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. , 2010, Cancer cell.
[27] M. McCue. Starvation physiology: reviewing the different strategies animals use to survive a common challenge. , 2010, Comparative biochemistry and physiology. Part A, Molecular & integrative physiology.
[28] L. Zitvogel,et al. The IKK complex contributes to the induction of autophagy , 2010, The EMBO journal.
[29] Robert V Farese,et al. SIRT3 regulates fatty acid oxidation via reversible enzyme deacetylation , 2009, Nature.
[30] S. Akira,et al. Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis , 2009, Proceedings of the National Academy of Sciences.
[31] Dorothy D. Sears,et al. Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitization , 2009, Proceedings of the National Academy of Sciences.
[32] M. Czaja,et al. Autophagy regulates lipid metabolism , 2009, Nature.
[33] Qing Xu,et al. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. , 2009, Cell metabolism.
[34] A. López-Rivas,et al. TAK1 activates AMPK‐dependent cytoprotective autophagy in TRAIL‐treated epithelial cells , 2009, The EMBO journal.
[35] Michiie Sakamoto,et al. Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia , 2009, Hepatology.
[36] J. Storch,et al. Metabolism of apical versus basolateral sn-2-monoacylglycerol and fatty acids in rodent small intestine** This work was supported by National Institutes of Health Grant DK-38389 and the Busch Biomedical Research Fund. Published, JLR Papers in Press, April 17, 2008. , 2008, Journal of Lipid Research.
[37] D. Rader,et al. Knockdown of acyl-CoA:diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion in mice. , 2008, Biochimica et biophysica acta.
[38] D. Brenner,et al. High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate–activated protein kinase , 2008, Hepatology.
[39] J. LoPiccolo,et al. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[40] T. Luedde,et al. Hepatic NF-κB essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis , 2008, Proceedings of the National Academy of Sciences.
[41] L. Sanderson,et al. Comprehensive Analysis of PPARα-Dependent Regulation of Hepatic Lipid Metabolism by Expression Profiling , 2007, PPAR research.
[42] Shao-Cong Sun,et al. Retroviral oncoprotein Tax deregulates NF‐κB by activating Tak1 and mediating the physical association of Tak1–IKK , 2007, EMBO reports.
[43] L. Terracciano,et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis , 2007, Hepatology.
[44] T. Luedde,et al. Deletion of NEMO/IKKγ in Liver Parenchymal Cells Causes Steatohepatitis and Hepatocellular Carcinoma , 2007 .
[45] Michael D. Schneider,et al. A pivotal role for endogenous TGF-β-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway , 2006, Proceedings of the National Academy of Sciences.
[46] M. Karin. Nuclear factor-κB in cancer development and progression , 2006, Nature.
[47] Ki-Young Lee,et al. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. , 2005, Genes & development.
[48] S. Akira,et al. Essential function for the kinase TAK1 in innate and adaptive immune responses , 2005, Nature Immunology.
[49] Michael Karin,et al. IKKβ Couples Hepatocyte Death to Cytokine-Driven Compensatory Proliferation that Promotes Chemical Hepatocarcinogenesis , 2005, Cell.
[50] Trey Ideker,et al. VAMPIRE microarray suite: a web-based platform for the interpretation of gene expression data , 2005, Nucleic Acids Res..
[51] Shankar Subramaniam,et al. Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes , 2004, Bioinform..
[52] S. Kersten,et al. Peroxisome proliferator-activated receptor α target genes , 2004, Cellular and Molecular Life Sciences CMLS.
[53] M. Matsui,et al. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. , 2003, Molecular biology of the cell.
[54] F. Gonzalez,et al. The role of the peroxisome proliferator-activated receptor α (PPARα) in the control of cardiac lipid metabolism , 1999 .
[55] F. Gonzalez,et al. The role of the peroxisome proliferator-activated receptor alpha (PPAR alpha) in the control of cardiac lipid metabolism. , 1999, Prostaglandins, leukotrienes, and essential fatty acids.